BR0110024A - Derivados de ecteinascidina antitumorais - Google Patents

Derivados de ecteinascidina antitumorais

Info

Publication number
BR0110024A
BR0110024A BR0110024-6A BRPI0110024A BR0110024A BR 0110024 A BR0110024 A BR 0110024A BR PI0110024 A BRPI0110024 A BR PI0110024A BR 0110024 A BR0110024 A BR 0110024A
Authority
BR
Brazil
Prior art keywords
antitumor
derivatives
compounds
ecteinascidin
ecteinascidin derivatives
Prior art date
Application number
BR0110024-6A
Other languages
English (en)
Inventor
Maria Flores
Andres Francesch
Pilar Gallego
Jose Luis Chicharro
Maria Zarzuelo
Carolina Fernandez
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009043A external-priority patent/GB0009043D0/en
Priority claimed from PCT/GB2000/001852 external-priority patent/WO2000069862A2/en
Priority claimed from GB0022644A external-priority patent/GB0022644D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0110024A publication Critical patent/BR0110024A/pt
Publication of BRPI0110024B1 publication Critical patent/BRPI0110024B1/pt
Publication of BRPI0110024B8 publication Critical patent/BRPI0110024B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"DERIVADOS DE ECTEINASCIDINA ANTITUMORAIS". A invenção refere-se a compostos que têm um sistema fundido de cinco anéis de ecteinascidina com uma ponte 1,4 tendo a estrutura de fórmula (VIa ou VIb) e compostos nos quais o -NH~ 2~ ou o -OH da ponte 1,4 é derivatizado. Tais compostos são úteis no tratamento de tumores.
BRPI0110024-6 2000-04-12 2001-04-12 derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos BRPI0110024B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0009043A GB0009043D0 (en) 2000-04-12 2000-04-12 New autitumoural derivatives of ET-743
GB0009043.1 2000-04-12
GBPCT/GB00/01852 2000-05-15
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof
GB0022644.9 2000-09-14
GB0022644A GB0022644D0 (en) 2000-09-14 2000-09-14 Antitumoral derivatives of ET-743
PCT/GB2001/001667 WO2001077115A1 (en) 2000-04-12 2001-04-12 Antitumoral ecteinascidin derivatives

Publications (3)

Publication Number Publication Date
BR0110024A true BR0110024A (pt) 2003-02-18
BRPI0110024B1 BRPI0110024B1 (pt) 2019-07-16
BRPI0110024B8 BRPI0110024B8 (pt) 2021-05-25

Family

ID=26244092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0110024-6 BRPI0110024B8 (pt) 2000-04-12 2001-04-12 derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos

Country Status (27)

Country Link
US (1) US7202361B2 (pt)
EP (1) EP1280809B1 (pt)
JP (1) JP5219323B2 (pt)
KR (1) KR100886496B1 (pt)
CN (1) CN1436191B (pt)
AR (1) AR032879A1 (pt)
AT (1) ATE299146T1 (pt)
AU (1) AU784249C (pt)
BG (1) BG65987B1 (pt)
BR (1) BRPI0110024B8 (pt)
CA (1) CA2406080C (pt)
CZ (1) CZ304749B6 (pt)
DE (1) DE60111845T2 (pt)
DK (1) DK1280809T3 (pt)
EA (1) EA006206B1 (pt)
ES (1) ES2244598T3 (pt)
HK (1) HK1049005B (pt)
HU (1) HU230918B1 (pt)
IL (1) IL152094A (pt)
MX (1) MXPA02010088A (pt)
NO (1) NO329125B1 (pt)
NZ (1) NZ521550A (pt)
PL (1) PL210703B1 (pt)
PT (1) PT1280809E (pt)
SI (1) SI1280809T1 (pt)
SK (1) SK288017B6 (pt)
WO (1) WO2001077115A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
JP4208469B2 (ja) * 2002-01-29 2009-01-14 独立行政法人科学技術振興機構 エクテナサイジン類の全合成方法、エクテナサイジン類に類縁構造を持つ前記全合成用中間体化合物類、及び該中間体化合物類の合成方法
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
AU2005288696A1 (en) * 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
WO2006083417A2 (en) * 2004-12-20 2006-08-10 The Trustees Of Columbia University In The City Of New York Processes of making sesquiterpenoid tashironin, its analogs and their uses
US20090131498A1 (en) * 2005-01-18 2009-05-21 Danishefsky Samuel J Enantioselective Synthesis of Merrilactone and Its Analogs
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007087220A2 (en) * 2006-01-25 2007-08-02 The Trustees Of Columbia University In The City Of New York The total synthesis of ecteinascidin 743 and derivatives thereof
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
CN107033164A (zh) 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
CN112679513B (zh) * 2019-10-18 2023-08-25 南通诺泰生物医药技术有限公司 一种制备曲贝替定的关键中间体的方法
JP2023503318A (ja) 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
CN115677728A (zh) * 2022-11-02 2023-02-03 成都科岭源医药技术有限公司 一种海鞘素类化合物中间体的制备方法
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
HK1049005B (en) 2006-01-27
ES2244598T3 (es) 2005-12-16
HK1049005A1 (en) 2003-04-25
SK288017B6 (sk) 2012-11-05
NO329125B1 (no) 2010-08-30
PL210703B1 (pl) 2012-02-29
BRPI0110024B8 (pt) 2021-05-25
HUP0300534A2 (hu) 2003-07-28
KR100886496B1 (ko) 2009-03-05
JP2003530402A (ja) 2003-10-14
DE60111845D1 (de) 2005-08-11
CN1436193A (zh) 2003-08-13
DE60111845T2 (de) 2006-04-27
SK14352002A3 (sk) 2003-04-01
NO20024906D0 (no) 2002-10-11
PT1280809E (pt) 2005-11-30
HU230918B1 (hu) 2019-03-28
EA200201083A1 (ru) 2003-04-24
NO20024906L (no) 2002-11-27
AR032879A1 (es) 2003-12-03
AU784249C (en) 2007-05-03
WO2001077115A1 (en) 2001-10-18
SI1280809T1 (sl) 2005-12-31
CZ20023352A3 (cs) 2003-05-14
HUP0300534A3 (en) 2006-02-28
IL152094A0 (en) 2003-05-29
CN1436191B (zh) 2011-09-14
ATE299146T1 (de) 2005-07-15
AU784249B2 (en) 2006-02-23
IL152094A (en) 2011-10-31
MXPA02010088A (es) 2004-08-19
EP1280809A1 (en) 2003-02-05
DK1280809T3 (da) 2005-11-07
BRPI0110024B1 (pt) 2019-07-16
NZ521550A (en) 2004-10-29
BG65987B1 (bg) 2010-08-31
BG107220A (en) 2003-05-30
AU4672901A (en) 2001-10-23
PL357574A1 (en) 2004-07-26
CA2406080C (en) 2011-11-29
EA006206B1 (ru) 2005-10-27
US7202361B2 (en) 2007-04-10
CZ304749B6 (cs) 2014-09-24
US20030216397A1 (en) 2003-11-20
CA2406080A1 (en) 2001-10-18
EP1280809B1 (en) 2005-07-06
JP5219323B2 (ja) 2013-06-26
KR20030012864A (ko) 2003-02-12

Similar Documents

Publication Publication Date Title
BR0110024A (pt) Derivados de ecteinascidina antitumorais
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BRPI0111222B8 (pt) derivados fosfonados de glicopeptídeo.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
ATE246490T1 (de) Pharmazeutische zusammensetzung von topiramate
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
TR200000223T2 (tr) XA faktörünü engelleyen heterosiklik türevler
DE60121461D1 (de) Kondensierte pyridoindolderivate
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
TR200101649T2 (tr) Piperazin türevleri.
ATE277062T1 (de) Neue makrolidderivate
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
BR9812160A (pt) Derivados de benzoxazina e benzotiazina e seu emprego em medicamentos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/04/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/04/2021